


WENZEL et al., Serial No. 09/782,306

BEST AVAILABLE COPY


AMENDMENTS TO THE CLAIMS

1. (previously presented) A composition for inhibiting COX-2 biosynthesis or COX-2- and NF $\kappa$ B-biosynthesis comprising a therapeutically effective amount of the compound of formula I



wherein R<sup>1</sup> and R<sup>4</sup> represent either hydrogen or together a bond, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> represent independently of each other hydrogen, hydroxy or methoxy; in addition R<sup>7</sup> represents a sugar substituent,

R<sup>2</sup> and R<sup>3</sup> represent hydrogen, hydroxy, methoxy, or




, wherein R<sup>2'</sup>, R<sup>3'</sup>, R<sup>5'</sup>, and R<sup>6'</sup> are independently of each

other hydrogen, hydroxy or methoxy, wherein R<sup>4'</sup> is H, flavone, 5-OH-flavone, 7-OH-flavone and 7,8-(OH)<sub>2</sub>-flavone, with the proviso, that R<sup>2</sup> or R<sup>3</sup> is represented by the phenyl-ring optionally substituted and a pharmaceutically acceptable carrier.

2. (previously presented) A composition for inhibiting COX-2 biosynthesis or NF $\kappa$ B-biosynthesis or NF $\kappa$ B and COX-2 biosynthesis comprising a therapeutically effective amount of the compound of formula II

WENZEL et al., Serial No. 09/782,306

BEST AVAILABLE COPY



wherein  $R^3$  represents hydrogen, hydroxy or methoxy and  $R^5, R^6, R^7, R^8, R^{2'}, R^{3'}, R^{5'}, R^{6'}$  are as given in claim 1 and a pharmaceutical acceptable carrier.

3-12. (canceled)

13. (currently amended) The composition of claim 1, wherein the sugar substituent is selected from the group consisting of ~~hydrogen, hydroxy, methoxy,~~ glucoside, rutinosid, manno gluco pyransyl, and aprosylglucoside.